We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
California’s biomedical industry has become the second largest contributor to the state’s high-technology economy, but concerns exist about the industry’s future, according to a report from the California Healthcare Institute (CHI).
The international drug development services company formerly known as SFBC International announced Aug. 28 that it has formally changed its corporate name to PharmaNet Development Group.
The U.S. International Trade Commission (ITC) has decided not to review a decision made earlier this year that Roche’s importation and use of its experimental anemia drug Mircera in the U.S. did not violate Amgen’s patents on its anemia drug Epogen.
VaxGen’s experimental anthrax vaccine could be a viable alternative to the presently available treatment, according to a study published in the August issue of the medical journal Vaccine.
The Biotechnology Industry Organization (BIO) is praising an Aug. 9 decision by the SEC to give smaller public companies additional time to comply with the internal control requirements under the Sarbanes-Oxley Act (SOX).
The biotech industry got a partial victory in its effort to allow more venture capital-backed firms to receive research funding when compromise legislative language passed out of committee July 27.
The biotech industry got a partial victory in its efforts to allow more venture capital-backed firms to receive research funding when compromise legislative language passed out of committee July 27.